These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 11196741)
1. Reactogenicity and immunogenicity of a new measles-mumps-rubella vaccine containing RIT 4385 mumps virus strain in healthy Turkish children. Kanra G; Ceyhan M; Ozmert E Turk J Pediatr; 2000; 42(4):275-7. PubMed ID: 11196741 [TBL] [Abstract][Full Text] [Related]
2. A randomized comparative trial in order to assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when given as a first dose at 12-24 months of age. Gatchalian S; Cordero-Yap L; Lu-Fong M; Soriano R; Ludan A; Chitour K; Bock HL Southeast Asian J Trop Med Public Health; 1999 Sep; 30(3):511-7. PubMed ID: 10774661 [TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine. Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835 [TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age. Goh P; Lim FS; Han HH; Willems P Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370 [TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years. Vesikari T; Baer M; Willems P Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879 [TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of a varicella vaccine, Okavax, and a trivalent measles, mumps and rubella vaccine, MMR-II, administered concomitantly in healthy Filipino children aged 12-24 months. Gatchalian S; Leboulleux D; Desauziers E; Bermal N; Borja-Tabora C Southeast Asian J Trop Med Public Health; 2003 Sep; 34(3):589-97. PubMed ID: 15115135 [TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age. Nolan T; Bernstein DI; Block SL; Hilty M; Keyserling HL; Marchant C; Marshall H; Richmond P; Yogev R; Cordova J; Cho I; Mendelman PM; Pediatrics; 2008 Mar; 121(3):508-16. PubMed ID: 18310199 [TBL] [Abstract][Full Text] [Related]
8. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella. Nascimento Silva JR; Camacho LA; Siqueira MM; Freire Mde S; Castro YP; Maia Mde L; Yamamura AM; Martins RM; Leal Mde L; Vaccine; 2011 Aug; 29(37):6327-34. PubMed ID: 21640779 [TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age. Halperin SA; Ferrera G; Scheifele D; Predy G; Stella G; Cuccia M; Douha M; Willems P Vaccine; 2009 May; 27(20):2701-6. PubMed ID: 19428882 [TBL] [Abstract][Full Text] [Related]
10. Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella. Wellington K; Goa KL Drugs; 2003; 63(19):2107-26. PubMed ID: 12962524 [TBL] [Abstract][Full Text] [Related]
11. Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children. Usonis V; Bakasenas V; Kaufhold A; Chitour K; Clemens R Pediatr Infect Dis J; 1999 Jan; 18(1):42-8. PubMed ID: 9951979 [TBL] [Abstract][Full Text] [Related]
12. [Studies on the safety and immunogenicity of lyophilized live attenuated measles-mumps-rubella combined vaccine]. Liu G; Fang H; Feng Z; Guo W; Dong C; Zhang W; Ze W Zhonghua Liu Xing Bing Xue Za Zhi; 2002 Dec; 23(6):435-7. PubMed ID: 12667354 [TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of two tetravalent (measles, mumps, rubella, varicella) vaccines coadministered with hepatitis a and pneumococcal conjugate vaccines to children twelve to fourteen months of age. Blatter MM; Klein NP; Shepard JS; Leonardi M; Shapiro S; Schear M; Mufson MA; Martin JM; Varman M; Grogg S; London A; Cambron P; Douha M; Nicholson O; da Costa C; Innis BL Pediatr Infect Dis J; 2012 Aug; 31(8):e133-40. PubMed ID: 22622699 [TBL] [Abstract][Full Text] [Related]
14. Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children. Feiterna-Sperling C; Brönnimann R; Tischer A; Stettler P; Durrer P; Gaedicke G Pediatr Infect Dis J; 2005 Dec; 24(12):1083-8. PubMed ID: 16371870 [TBL] [Abstract][Full Text] [Related]
15. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody. Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ; Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432 [TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15 months: A phase III, randomized, non-inferiority trial. MMR-161 Study Group Vaccine; 2018 Sep; 36(38):5781-5788. PubMed ID: 30104117 [TBL] [Abstract][Full Text] [Related]
17. Comparative study of reactogenicity and immunogenicity of new and established measles, mumps and rubella vaccines in healthy children. Usonis V; Bakasenas V; Chitour K; Clemens R Infection; 1998; 26(4):222-6. PubMed ID: 9717679 [TBL] [Abstract][Full Text] [Related]
18. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax. Reisinger KS; Brown ML; Xu J; Sullivan BJ; Marshall GS; Nauert B; Matson DO; Silas PE; Schödel F; Gress JO; Kuter BJ; Pediatrics; 2006 Feb; 117(2):265-72. PubMed ID: 16452343 [TBL] [Abstract][Full Text] [Related]
19. The immunogenicity and reactogenicity of the trivalent vaccine, Trimovax, indicated for prevention of measles, mumps, and rubella, in 12-month-old children in Belarus. Samoilovich EO; Kapustik LA; Feldman EV; Yermolovich MA; Svirchevskaya AJ; Zakharenko DF; Fletcher MA; Titov LP Cent Eur J Public Health; 2000 Aug; 8(3):160-3. PubMed ID: 10965439 [TBL] [Abstract][Full Text] [Related]
20. A new measles mumps rubella (MMR) vaccine: a randomized comparative trial for assessing the reactogenicity and immunogenicity of three consecutive production lots and comparison with a widely used MMR vaccine in measles primed children. Lee CY; Tang RB; Huang FY; Tang H; Huang LM; Bock HL Int J Infect Dis; 2002 Sep; 6(3):202-9. PubMed ID: 12718836 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]